類風濕性關節炎（RA）：新型療法、未滿足的需求和目標產品展望報告，2026 年

市場概覽

• 受大規模的患者群體和生物製藥的高普及率推動，德國類風濕性關節炎 (RA) 市場預計將從 31.53 億美元擴大到 35.54 億美元。
• 西班牙中度至重度類風濕性關節炎市場預計將從 7.7 億美元成長到 8.38 億美元，反映出市場正在逐步擴張。
• 以下因素正在推動市場成長：
• 擴大生物製藥和JAK抑制劑的應用
• 慢性病管理中治療療程的延長
• 雖然患者數量的成長保持穩定到中等水平，但市場規模的成長是由高附加價值治療方法和聯合治療推動的。
• 未來的成長取決於下一代標靶治療和緩解疾病策略的改進。

類風濕性關節炎(RA) 的新治療方法及對 TPP 的深入研究

Thelansis 的《類風濕性關節炎(RA) 新興治療方法、未滿足的需求和 TPP 洞察報告 - 2026》對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

類風濕性關節炎概述

類風濕性關節炎（RA）是一種慢性全身性自體免疫疾病，其特徵是滑膜持續炎症，導致進行性性關節破壞、疼痛、僵硬、腫脹和不可逆功能障礙。此疾病會擴散到關節以外，並常伴隨心血管疾病、間質性肺病、骨質疏鬆症和慢性疲勞等全身性併發症，顯著增加發病率和死亡率。

在中重度階段，患者的日常生活活動和生活品質會顯著受損。疾病活動度評估採用綜合指標（如DAS28、CDAI），並輔以類風濕因子（RF）和抗環瓜氨酸肽（抗CCP）抗體等血清學標記。疾病進展是由複雜的免疫調節異常引起的，涉及促炎細胞激素，特別是TNF-α、IL-6和JAK-STAT訊號通路。

治療以目標-治療（T2T）為核心，強調早期積極干預，以達到持續緩解或低疾病活動。傳統的合成DMARDs，特別是胺基甲基葉酸，仍然是治療的基礎，並且經常與生物DMARDs（例如TNF抑製劑、IL-6受體拮抗劑）或靶向合成藥物（例如JAK抑製劑）聯合使用，用於治療反應不足的患者。糖皮質激素和非類固醇抗發炎藥（NSAIDs）可作為輔助性治療，用於快速控制症狀，但不適用於長期緩解疾病。

儘管治療方法取得了顯著進展，但仍有相當一部分患者會出現原發性或繼發性治療失敗、疾病持續活動或治療不耐受等問題，需要多次更換治療方案。此外，長期安全性問題、高昂的治療費用以及治療反應的個體差異仍然是實現最佳疾病管理的挑戰。

治療前景日益聚焦於精準醫療，將基於生物標記的患者分層、新型免疫標靶和最佳化的治療順序策略相結合，以增強持續療效。未來的創新旨在攻克難治性疾病，最大限度地減少全身併發症，並最終實現持續緩解，同時提高安全性和以患者為中心的治療效果。

主要亮點

• 在德國，預計患病人數將從 1,046,761 人增加到 1,122,386 人，這持續表明存在大規模患者群體。
• 在法國，中度至重度類風濕性關節炎 (RA) 患者人數預計將從 309,511 人增加到 331,872 人，反映出疾病負擔的穩定上升。
• 中度至重度類風濕性關節炎 (RA) 仍會因進行性性關節損傷和全身性併發症而導致嚴重的身體殘疾。
• 儘管有先進的生物製藥和標靶治療，但治療抗藥性和疾病復發仍然很常見。
• 為了改善長期治療效果，個人化醫療和基於生物標記的治療方法正受到越來越多的關注。

基於對醫生和關鍵意見領袖（KOL）的調查得出的結論：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 主要企業
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 估算主要未滿足需求的市場規模
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Kali Therapeutics, Inc.
• Surf Therapeutics
• Philogen SpA
• Qilu Pharmaceutical Co., Ltd.
• Toll Biotech Co. Ltd.（Beijing）
• Shanghai Kanda Biotechnology Co., Ltd.
• Kashiv BioSciences, LLC
• Lynk Pharmaceuticals Co., Ltd
• Eli Lilly and Company
• Merck Sharp &Dohme LLC
• Novartis Pharmaceuticals
• AstraZeneca
• Bristol-Myers Squibb
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Shenzhen MagicRNA Biotechnology Co., Ltd
• AbbVie
• Sanofi
• Lifordi Immunotherapeutics, Inc.
• Capstan Therapeutics
• Seismic Therapeutic AU Pty Ltd

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Rheumatoid Arthritis (RA) Emerging Therapy and TPP Insights

Thelansis's "Rheumatoid Arthritis (RA) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder characterized by persistent inflammation of the synovial membrane, leading to progressive joint destruction, pain, stiffness, swelling, and irreversible functional disability. The disease extends beyond joints, frequently manifesting with systemic complications such as cardiovascular disease, interstitial lung disease, osteoporosis, and chronic fatigue, significantly increasing morbidity and mortality risk.

At moderate to severe stages, patients experience substantial impairment in daily functioning and quality of life, with disease activity assessed using composite indices (e.g., DAS28, CDAI) and supported by serological biomarkers such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Disease progression is driven by complex immune dysregulation involving pro-inflammatory cytokines, particularly TNF-a, IL-6, and JAK-STAT signaling pathways.

Management is centered on a treat-to-target (T2T) approach, emphasizing early, aggressive intervention to achieve sustained remission or low disease activity. Conventional synthetic DMARDs, particularly methotrexate, remain the backbone of therapy and are frequently combined with biologic DMARDs (e.g., TNF inhibitors, IL-6 receptor antagonists) or targeted synthetic agents such as JAK inhibitors for patients with inadequate response. Corticosteroids and NSAIDs are used adjunctively for rapid symptom control but are not suitable for long-term disease modification.

Despite significant therapeutic advancements, a considerable proportion of patients exhibit primary or secondary treatment failure, persistent disease activity, or intolerance to therapies, necessitating multiple treatment switches. Additionally, long-term safety concerns, high treatment costs, and heterogeneity in treatment response continue to pose challenges in optimal disease management.

The evolving treatment landscape is increasingly focused on precision medicine, incorporating biomarker-driven patient stratification, novel immune targets, and optimized sequencing strategies to improve durability of response. Future innovation aims to address refractory disease, minimize systemic complications, and ultimately achieve sustained remission with improved safety and patient-centric outcomes..

Key Highlights

• In Germany, prevalence is expected to grow from 1,046,761 to 1,122,386, indicating a consistently large patient pool.
• In France, prevalent moderate to severe RA cases are projected to increase from 309,511 to 331,872, reflecting a steady rise in disease burden.
• Moderate to severe RA continues to drive significant disability due to progressive joint damage and systemic complications.
• Despite availability of advanced biologics and targeted therapies, treatment resistance and disease flares remain common.
• Increasing focus on personalized medicine and biomarker-driven treatment selection to improve long-term outcomes.

Market Overview

• The Germany RA market is expected to increase from $3,153M to $3,554M, driven by a large patient base and high biologic adoption.
• The Spain moderate to severe RA market is projected to grow from $770M to $838M, reflecting moderate expansion.
• Market growth is supported by:
• Increased uptake of biologics and JAK inhibitors
• Longer treatment duration in chronic disease management
• Despite stable-to-moderate patient growth, market value is driven by premium therapies and combination treatment approaches.
• Future growth will depend on next-generation targeted therapies and improved disease-modifying strategies.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Kali Therapeutics, Inc.
• Surf Therapeutics
• Philogen S.p.A.
• Qilu Pharmaceutical Co., Ltd.
• Toll Biotech Co. Ltd. (Beijing)
• Shanghai Kanda Biotechnology Co., Ltd.
• Kashiv BioSciences, LLC
• Lynk Pharmaceuticals Co., Ltd
• Eli Lilly and Company
• Merck Sharp & Dohme LLC
• Novartis Pharmaceuticals
• AstraZeneca
• Bristol-Myers Squibb
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Shenzhen MagicRNA Biotechnology Co., Ltd
• AbbVie
• Sanofi
• Lifordi Immunotherapeutics, Inc.
• Capstan Therapeutics
• Seismic Therapeutic AU Pty Ltd

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)